Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606900 | 0.92 | NPC1 (0.52) | ALOX5KMT2AMEN1ALDH1A1MAPT | |
| Phenylboronic Acid SCHEMBL6611114 | 0.91 | ALOX5 (0.51) | ALOX5KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL8413415 | 0.91 | HTT (0.56) | ALOX5KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL8413418 | 0.88 | HTT (0.51) | ALOX5KMT2AMEN1MAPTPOLB | |
| SCHEMBL311833 | 0.87 | MEN1 (0.53) | ALOX5KMT2AMEN1MAPTLMNA | |
| SCHEMBL29727627 | 0.86 | MEN1 (0.60) | ALOX5KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL2684708 | 0.86 | KMT2A (0.52) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL18496690 | 0.86 | MEN1 (0.60) | ALOX5KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL18172331 | 0.86 | POLB (0.47) | ALOX5KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL16050355 | 0.85 | NPC1 (0.63) | ALOX5KMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1703395-A | Aryl and heteroaryl compounds and methods of modulating blood coagulation | TRANSTECH PHARMA INC (US) | 2005-11-30 | — | — | CN | claimed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| CN-1256334-C | Alkoxycarbonylaminobenzoic acid or alkoxycarbonylaminotetrazolylphenyl derivatives as IP antagonists | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | CN | disclosed |
| EP-1379516-B1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | disclosed |
| US-6903086-B2 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1379516-A1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2002-11-07 | — | — | US | disclosed |
| WO-2002070500-A1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | GPBAR1, GABRP, TBXA2R | ALOX5 590/4885KMT2A 4499/4885MEN1 3180/4885 |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | ALOX5 483/4885KMT2A 3655/4885MEN1 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.